Vistagen Therapeutics ($VTGN) Failed Phase 3 Trial and Misleading Clinical Expectations Case

Investors can submit applications for the lead plaintiff role.

N.D. California

Court

3:26-cv-00427

Case number

04/01/2024

Class period Start

12/16/2025

Class period End

03/16/2026

Lead Plaintiff motion deadline

$VTGN investors filed a claim against Vistagen Therapeutics Inc. for allegedly overstating the likelihood of success in its key Phase 3 clinical trial for fasedienol, a treatment for Social Anxiety Disorder (SAD), while downplaying known risks tied to placebo response variability.
After announcing that the PALISADE-3 trial failed to meet its primary and secondary endpoints, $VTGN dropped over 80% on December 17, 2025, falling from $4.36 to $0.86 in one day.
$VTGN investors can join this case to be notified about potential recovery.
Case Details:

Between April 1, 2024, and December 16, 2025, Vistagen repeatedly told investors it was confident in the outcome of its PALISADE-3 Phase 3 trial for fasedienol, citing design enhancements, site selection improvements, and prior positive results from PALISADE-2. Executives promoted PALISADE-3 as a “confirmatory” study and expressed confidence that the trial would support future FDA approval.

However, the company allegedly failed to disclose ongoing risks in the study design—particularly the high susceptibility to placebo responses in public speaking challenge-based trials. Despite these concerns, Vistagen reaffirmed its optimistic clinical outlook throughout the class period.

On December 17, 2025, Vistagen disclosed that PALISADE-3 failed to achieve both its primary and secondary endpoints, showing no significant separation between fasedienol and placebo. The news triggered a dramatic one-day stock drop of over 80%, with $VTGN closing at $0.86, down from $4.36 the previous day.

Based on these events, $VTGN investors filed a claim against Vistagen, alleging the company:
It misrepresented the likelihood of success in its lead clinical trial for fasedienol.
It failed to disclose known risks tied to placebo sensitivity in trial design.
It misled investors by portraying PALISADE-3 as confirmatory and likely to succeed.
Investors argue Vistagen provided an overly optimistic view of its drug development progress, leading to steep losses when the trial failed and the truth was revealed.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Failure to Disclose

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

12/17/2025

Filing date

01/15/2026

Lead Plaintiff Deadline

03/16/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.